Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis.

Background: The present study aimed to address the effect of Rituximab on the cognitive impairment in patients with secondary progressive MS (SPMS). Methods: The present interventional study used a convenience sampling method to select the study participants from SPMS patients. All these patients had progressive disability over the last two years before being admitted in the study. Prior to the administration of Rituximab, the minimal assessment of cognitive function in the multiple sclerosis (MACFIMS) test was performed for each patient who was a candidate to be included in this study. This test was repeated by passing 6 and 12 months from the initial treatment with Rituximab. Since the data needed for this study were obtained at different time intervals, so a linear mixed model was used for their analysis. Analysis of variance (ANOVA) was also used to investigate whether time and sex generally affect the cognitive impairments in SPMS patients. A p-value <0.05 was considered as statistically significant in this study. Results: Of the total 35 patients, 34% and 66% were men and women with a mean age of 41.33 and 41.39 years old, respectively. Rituximab showed a significant positive effect on a number of subgroups of MACFIMS test, including Controlled Oral Word Association Test (COWAT) (P-value: 0.038) and Brief Visuospatial Memory Test (BVMT-total) (P: 0.019). Conclusion: The present study revealed that Rituximab has a positive effect on the cognitive impairment resulted from MS in secondary progressive patients.

Evaluation of types of psychological disorders in patients with neuromyelitis optica spectrum disorder (NMOSD).

BACKGROUND: Neuromyelitis Optica Spectrum Disorder (NMOSD), commonly characterized by affecting optic nerves and spinal cord can be regarded as one of uncommon diseases of the central nervous system. Although the evidence presented in the literature supports cognitive impairments, psychological aspects of the disease and its association with various manifestations of the disease have not been thoroughly studied. Therefore, the present study was conducted to investigate psychological aspects of patients with NMOSD compared to healthy individuals. MATERIALS AND METHODS: The patients' demographic information including their age and gender as well as the information about their disease including duration of the symptoms, the age at onset of symptoms, and NMO antibody status were collected using a specific questionnaire. Then, age- and gender-matched control participants that neither themselves nor their relatives had mentioned disease were included in the study. Then, Symptom Checklist-90 (SCL-90) test was administered to both groups. RESULTS: A total of 36 patients including 32 females and 4 males participated in the NMOSD group. In the control group, 37 healthy individuals including 30 females and 7 males took part in the study. Findings of the present study indicated that, patients with NMOSD significantly suffered from psychological disorders such as depression, anxiety, hostility, and somatization compared to healthy controls. The phobic anxiety and psychoticism showed trends toward being worse. However, obsessive compulsive symptoms, interpersonal sensitivity and paranoid ideation did not have significant differences between the two groups. CONCLUSION: According to results of the present study, as psychological disorders are common among patients with NMOSD, they should be thoroughly examined to offer more effective therapies in this regard. In addition, the psychological manifestations of NMOSD may influence patients' relationship, occupation and treatment compliance. So, evaluation of these factors is important in these patients.

Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study.

BACKGROUND: Anti-CD20 monoclonal antibodies such as ocrelizumab, rituximab, and ofatumumab target B-cell lineage. Clinical trials have demonstrated their effect on reducing both magnetic resonance imaging (MRI) active lesion burden as well as clinical activity. Zytux™ (Rituximab, AryoGen Pharmed) used in the present study for multiple sclerosis (MS) patients is basically a biosimilar rituximab. In this observational study, a total of 100 patients receiving Zytux™ were collected to see its effect on the clinical course of the disease. MATERIALS AND METHODS: The files of 100 MS patients, who received Zytux™ in a referral center (Sina MS Clinic in Tehran, Iran), were analyzed as a hospital-based observational study. Patients' age and disease duration until the start of Zytux™, expanded disability status scale (EDSS) at the baseline and in the last visit after administration of the drug, and annual relapse rate (ARR) before and after initiating Zytux™ were studied. Disease activity was evaluated both clinically and via MRI. RESULT: A total of 100 MS patients including 36 males and 64 females participated in the present study. The patients included 20 relapsing remitting MS (RRMS), 20 primary progressive MS (PPMS), and 60 secondary progressive MS (SPMS) patients. Totally, the mean of EDSS score before and after the administration of drug was 5.50 ±â€¯1.04 (ranging from 1 to 7) and 5.11 ±â€¯1.59 (ranging from 0 to 7), respectively, with the difference between them being very significant (p-value: 0.000). Also, the mean of ARR before and after the initiation of the medication was 0.47 and 0.10, respectively, whose difference was also significant (p-value: 0.000). In our study, the greatest effect of Zytux™ was observed in RRMS patients. At the time of injection, 70 patients indicated some reactions including limb pain, skin sensitivity, and throat irritation. One month after the injection, one of the patients suffered from pneumonia and two patients had a urinary tract infection. CONCLUSION: The observed results revealed that the Zytux™ could have a positive and significant effect on all types of MS.